Skip to main content

Advertisement

SpringerLink
Log in

Comparison of New Drug Accessibility and Price Between Japan and Major European Countries

  • Global Perspectives: Original Research
  • Published:
Therapeutic Innovation & Regulatory Science Aims and scope Submit manuscript

Abstract

Background

A common concern about universal health insurance coverage is how to control health expenditure. The escalation of health care costs raises public awareness of the optimization of drug price and increased demand for cost-effectiveness assessment. In this paper, we show the differences in patient access to new drugs and drug price among countries, in which the situation of introduction of cost-effectiveness assessment scheme is different.

Methods

We investigated the health insurance coverage proportion of newly approved drugs in Japan, France, Germany, and the United Kingdom (UK). Then, we calculated the ratios of the European to the Japanese price for products that were reimbursed in both countries.

Results

Japan had the highest health insurance coverage proportion (98.6%) in the 4 countries. In Japan, all the drugs that were approved in 2015 had been already listed in the latest formulary of February 2016. As for drug price, there wasn’t much difference between Japan and the European countries in many cases.

Conclusion

From the viewpoint of the health insurance coverage proportion and the speed of reimbursement decision, the hurdle to access new drugs in Japan is lower than that in major European countries. While extensive coverage of health insurance and prompt reimbursement decision lower the hurdles to access new drugs and expand treatment options, they could lead to the increased medical expenditure. We should continue to discuss sustainable health insurance systems and drug price calculation schemes that properly reflect the drug’s clinical value while keeping the availability of new drugs to patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Centre for Innovation in Regulatory Science. R&D Briefing 59: the impact of the evolving regulatory environment on the approval of new medicines across six major authorities 2006-2015. http://www.cirsci.org/wp-content/uploads/2016/05/CIRS_RD_-Briefing_59_23052016.pdf. Accessed February 10, 2017.

  2. World Health Organization (WHO). The World Health Report Health Systems Financing: the path to universal coverage. http://www.who.int/whr/2010/10_summary_en.pdf?ua=1. Accessed February 10, 2017.

  3. Japanese Ministry of Health, Labour and Welfare (MHLW). Annual Health, Labour and Welfare. Report 2015. http://www.mhlw.go.jp/english/wp/wp-hw9/index.html. Accessed February 10, 2017.

  4. OECD. Health at a Glance 2013. http://www.oecd.org/els/health-systems/Health-at-a-Glance-2013.pdf. Accessed February 10, 2017.

  5. Shibuya K, Hashimoto H, Ikegami N, et al. Future of Japan’s system of good health at low cost with equity: beyond universal coverage. Lancet. 2011;378:1256–1273.

    Article  Google Scholar 

  6. Hashimoto H, Ikegami N, Shibuya K, et al. Cost containment and quality of care in Japan: is there a trade-off? Lancet. 2011;378:1174–1182.

    Article  Google Scholar 

  7. Japanese Ministry of Health, Labour and Welfare (MHLW). Handling of the cost-effectiveness assessment of pharmaceuticals and medical devices. http://www.mhlw.go.jp/file.jsp?id=330543&name=file/06-Seisakujouhou-12400000-Hokenkyoku/0000112354.pdf. Accessed February 10, 2017.

  8. European Federation of Pharmaceutical Industries and Associations (EFPIA). Patients’ W.A.I.T. indicator Report 2011. http://www.efpia.eu/documents/33/64/Market-Access-Delays. Accessed February 10, 2017.

  9. Pearce A, van Gool K, Haywood P, Haas M. Delays in access to affordable medicines: putting policy into perspective. Aust Health Rev. 2012;3:412–418.

    Article  Google Scholar 

  10. Mark R, Brett S. Access delay, access denied 2012 waiting for new medicines in Canada. https://www.fraserinstitute.org/sites/default/files/access-delayed-access-denied-2012.pdf. Accessed February 10, 2017.

  11. Pharmaceuticals and Medical Devices Agency (PMDA). The lists of approved new drugs. https://www.pmda.go.jp/review-services/drug-reviews/review-information/p-drugs/0010.html. Accessed February 10, 2017.

  12. European Medicines Agency (EMA). European public assessment reports. http://www.ema.europa.eu/ema/index.jsp?curl=pages%2Fmedicines%2Flanding%2Fepar_search.jsp&mid=WC0b01ac058001d124&searchTab=&alreadyLoaded=true&isNewQuery=true&status=Authorised&status=Withdrawn&status=Suspended&status=Refused&startLetter=View+all&keyword=Enter+keywords&searchType=name&taxonomyPath=&treeNumber=&searchGenericType=generics. Accessed February 10, 2017.

  13. Centre for Innovation in Regulatory Science. New drug approvals in ICH countries: 2002-2011. Focus on 2011. http://cirsci.org/sites/default/files/New%20drug%20approvals%20in%20ICH%20countries%2002-11%20for%20release.pdf. Accessed February 10, 2017.

  14. Centre for Innovation in Regulatory Science. New drug approvals in ICH countries: 2003-2012. Focus on 2012. http://www.cirsci.org/sites/default/files/CIRS_R&D_Briefing_52_May_2013.pdf. Accessed February 10, 2017.

  15. Centre for Innovation in Regulatory Science. New drug approvals in ICH countries: 2004-2013. Focus on 2013. http://cirsci.org/publications/CIRS_R&D_Briefing_54_%20ICH_approval_times_2004-2013_22apr2014.pdf. Accessed February 10, 2017.

  16. Centre for Innovation in Regulatory Science. New drug approvals in ICH countries: 2005-2014. Focus on facilitated regulatory pathways and orphan designations. http://www.cirsci.org/sites/default/files/CIRS_R&D_57_ICH_%20approval_%20times_2005-2014_%2006072015.pdf. Accessed February 10, 2017.

  17. Organization for Economic Co-operation and Development (OECD). Health at a glance 2015. http://www.oecd-ilibrary.org/docserver/download/8115071e.pdf?expires=1486781568&id=id&accname=guest&checksum=4335A0C053C824ADE0491DEE4EF4BCFD. Accessed February 10, 2017.

  18. Takayama A, Narukawa M. Pharmaceutical pricing and reimbursement in Japan: for faster, more complete access to new drugs. Therapeutic Innovation & Regulatory Science. 2016;50.

    Google Scholar 

  19. European Commission. Amended proposal for a Directive of the European Parliament and of the Council on the Transparency of Measures regulating the prices of medicinal products for human use and their inclusion in the scope of public health insurance systems. http://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:52013PC0168. Accessed February 10, 2017.

  20. IMS consulting group. Pricing & market access outlook, 2015/2016 edition. https://www.imshealth.com/files/web/Global/Services/P&MA_2015.pdf. Accessed February 10, 2017.

  21. Pretium. Drug tracker report: July 2010. http://www.pretium.com.au/drugtrackerPDF/Drug%20Tracker%20-%2010%2007.pdf. Published 2010. Accessed February 10, 2017.

  22. Medicine Australia. COMPARE (Comparison of Access and Reimbursement Environments): a report benchmarking Australia’s access to new medicines. https://medicinesaustralia.com.au/wp-content/uploads/sites/52/2015/03/20150331-pub-Compare_Edition1_March2015-FINAL.pdf. Accessed February 10, 2017.

  23. Japanese MHLW. Strategy of Sakigake. http://www.mhlw.go.jp/english/policy/health-medical/pharmaceuticals/140729-01.html. Accessed February 10, 2017.

  24. Kanavos PG, Vandoros S. Determinants of branded prescription medicine prices in OECD countries. Health Econ Policy Law 2011;6:1–31.

    Article  Google Scholar 

  25. Leopold C, Mantel-Teeuwisse AK, Seyfang L, et al. Impact of external price referencing on medicine prices—a price comparison among 14 European countries. South Med Rev 2012;5:34–41.

    PubMed  PubMed Central  Google Scholar 

  26. Leopold C, Mantel-Teeuwisse AK, Vogler S, de Joncheere K, Laing RO, Leufkens HGM. Is Europe still heading to a common price level for on-patent medicines? An exploratory study among 15 Western European countries. Health Policy 2013;112:209–16.

    Article  Google Scholar 

  27. Vogler S, Vitry A, Babar ZU. Cancer drugs in 16 European countries, Australia, and New Zealand: a cross-country price comparison study. Lancet Oncol. 2016;17:39–47.

    Article  Google Scholar 

  28. Vogler S, Zimmermann N, Habl C, Piessnegger J, Bucsics A. Discounts and rebates granted to public payers for medicines in European countries. South Med Rev. 2012;5:38–46.

    PubMed  PubMed Central  Google Scholar 

  29. Ferrario A, Kanavos P. Dealing with uncertainty and high prices of new medicines: a comparative analysis of the use of managed entry agreements in Belgium, England, the Netherlands and Sweden. Soc Sci Med. 2015;124:39–47.

    Article  Google Scholar 

  30. European Federation of Pharmaceutical Industries and Associations (EFPIA). Improving patient access to innovative medicines the framework in which differentiated pricing may offer a solution. http://www.efpia.eu/uploads/Modules/Documents/pac-280214-ai6-a1-differentiated-pricing-position-paper-final.pdf. Accessed February 10, 2017.

  31. Garattini S, Bertele V, Godman B, Haycox A, Wettermark B, Gustafsson L. Enhancing the rational use of new medicines across European healthcare systems—a Position Paper. Eur J Clin Pharmacol. 2008;64:1137–1138.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Clinical Medicine (Pharmaceutical Medicine), Kitasato University School of Pharmacy, 5-9-1 Shirokane, Minato-ku, Tokyo, 108-8641, Japan

    Akane Takayama MSc & Mamoru Narukawa PhD

Authors
  1. Akane Takayama MSc
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mamoru Narukawa PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Akane Takayama MSc.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Takayama, A., Narukawa, M. Comparison of New Drug Accessibility and Price Between Japan and Major European Countries. Ther Innov Regul Sci 51, 604–611 (2017). https://doi.org/10.1177/2168479017706716

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1177/2168479017706716

Keywords

Search

Navigation